Vancomycin-resistant enterococcus (VRE) is a well-known infectious complication among immunocompromised patients. We performed a retrospective analysis to identify risk factors for the development of VRE bacteremia (VRE-B) within 15 months after allogeneic hematopoietic cell transplantation (alloHCT) and to determine its prognostic importance for other post-transplant outcomes. Eight hundred consecutive adult patients who underwent alloHCT for hematologic diseases from 1997 to 2011 were included. Seventy-six (10%) developed VRE-B at a median of 46 days post transplant. Year of transplant, higher HCT comorbidity score, a diagnosis of ALL, unrelated donor and umbilical cord blood donor were all significant risk factors on multivariable analysis for the development of VRE-B. Sixty-seven (88%) died within a median of 1.1 months after VRE-B, but only four (6%) of these deaths were attributable to VRE. VRE-B was significantly associated with worse OS (hazard ratio 4.28, 95% confidence interval 3.23-5.66, P o 0.001) in multivariable analysis. We conclude that the incidence of VRE-B after alloHCT has increased over time and is highly associated with mortality, although not usually attributable to VRE infection. Rather than being the cause, this may be a marker for a complicated post-transplant course. Strategies to further enhance immune reconstitution post transplant and strict adherence to infection prevention measures are warranted.
INTRODUCTION
Vancomycin-resistant enterococcus (VRE) is an important cause of hospital-acquired infection. Resistance to vancomycin is an independent predictor of death among patients with enterococcal bacteremia. 1 Risk factors for acquiring this infection include a critically ill condition, immunocompromised status including HIV infection as well as liver and allogeneic hematopoietic cell transplantation (alloHCT), admission to the hospital from a longterm care facility, mucositis, history of drug abuse, prior exposure to parenteral vancomycin, serum creatinine ⩾ 1.1 mg/dL, as well as recent carbapenem or aminoglycoside therapy. [2] [3] [4] [5] Hematologic malignancy patients and those undergoing alloHCT are particularly at risk for infections due to prolonged periods of neutropenia and delayed immune reconstitution. Treatment-related complications after therapy for such patients include mucositis and GVHD, which disrupt the intestinal integrity and predispose to infection from bacterial translocation across the mucosa into the circulation. 3, 6, 7 These patients are also at significant risk for central line-associated bacteremia unrelated to disruption of intestinal integrity. VRE has been recognized as a cause of such central line-associated infections in both adult and pediatric hematologic malignancy patients. 8, 9 We previously reported that early onset VRE bacteremia (VRE-B) after alloHCT was associated with 100% mortality. 10 The current analysis was performed on a larger cohort of such patients to identify risk factors for the development of VRE infection after alloHCT and to determine its prognostic importance for other post-transplant outcomes.
SUBJECTS AND METHODS
All consecutive adult patients who underwent alloHCT for hematologic diseases at the Cleveland Clinic from 1997 to 2011 were included in the analysis. They included those previously described in our initial report. 10 Patients were treated on alloHCT protocols that were reviewed and approved by the Cleveland Clinic's Institutional Review Board with signed informed consent obtained from all patients. Patient and transplantation characteristics and outcomes were obtained from the institution's Unified Transplant Database, which prospectively collects these data on all consecutive transplant recipients in our institution. Patients also consented to have their clinical data entered in our transplant database. No additional consent was obtained from them to later analyze these data regarding VRE; however, this study was approved by our Institutional Review Board. Data on infections were captured in real time in this database and reviewed every 2 weeks by an infectious disease physician.
Bacteremia with VRE included those established by having at least one positive blood culture for which antimicrobial treatment was initiated at the discretion of the treating physician. We did not screen patients for VRE colonization and fecal surveillance was not performed to identify carriage of VRE in our patients or for other hospitalized patients in other units at our institution. The approach for diagnosing enterococcal bacteremia did not change throughout the study period. In addition, the practice of obtaining blood cultures with regard to sample size, timing, transport, processing, interpreting and reporting remained consistent over time. Rectal thermometers were not used and patients did not share rooms, toilets or shower facilities. No investigation was performed to assess whether cross-infection due to VRE occurred. In general, patients received a regular diet except for those with gastrointestinal GVHD who received a low microbial diet, but we did not culture food for VRE. Our patients were not placed in isolation for VRE infection. We used standard infection prevention precautions including strict hand hygiene before and after entering patient's rooms, but this did not include using gloves or gowns for every patient contact.
The GVHD grading was performed according to standard criteria for acute and chronic GVHD. 11, 12 T-cell complete donor chimerism and hematopoietic cell transplant comorbity index were defined as previously reported. 13, 14 OS was defined as the time from the date of transplantation until death from any cause. The cause of death was established by the treating clinician at the time of death. Ongoing VRE-B at the time of death was entered by the treating clinician as an attributable cause of death.
As there were 19 different hematologic diagnoses in the study population and only 76 VRE events, it is difficult to assess the association between diagnosis and VRE incidence in a standard fashion. Therefore, to account for diagnosis in our analysis, recursive partitioning analysis 15 was performed before the primary analysis. This allowed patients to be categorized into a smaller number of diagnosis groups in order that the VRE incidence was similar among patients of the same group and different for those outside that group. Recursive partitioning analysis identified two groups: ALL (111 patients; 15-month VRE incidence 18%) versus all other diagnoses (689 patients; 15-month VRE incidence 8%). These two groups were used in the remainder of the analysis.
Categorical variables are summarized as frequency counts and percentages. Continuous variables are summarized as the median and range. VRE incidence was estimated using the cumulative incidence method. Fine and Gray competing risk regression 16 was used to identify risk factors for VRE infection, with death before VRE infection as the competing risk. VRE incidence was found to be significant over time. To show incidence over time, we categorized patients into quartiles based on transplant date so that 200 patients were in each quartile. Cox proportional hazards analysis was used to identify prognostic factors for OS; VRE infection was analyzed as a time-varying covariate in this analysis. Results from Fine and Gray regression and Cox analysis are summarized as the hazard ratio, 95% confidence interval for the hazard ratio and corresponding P-value. Competing risk regression was done using the cmprsk package in R (Linux version 3.0.0, http://www.r-project.org/); all other analyses were done using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, and Po 0.05 was used to indicate statistical significance.
RESULTS
A total of 800 consecutive adult patients with hematologic diseases underwent alloHCT from 1997 to 2011. The baseline patient characteristics, transplant-related characteristics and posttransplant outcomes are summarized in Tables 1 and 2 . The majority of patients received myeloablative conditioning regimens and had 8/8 HLA-matched donors. BM was the most common graft source for myeloablative transplants while PBSC were used for the majority of reduced-intensity conditioning (RIC) transplants.
Seventy-six (10%) patients developed VRE infection within 15 months post transplant and 7 of these had later recurrences of VRE infection. All 76 were VRE-Bs. Thirteen (17%) had known prior VRE infection or colonization before alloHCT. The median duration of VRE infection with positive cultures was 4 consecutive days (range, 1-20 days). There were no documented cases of endocarditis. Sixty-four patients had central venous catheters in place at the time of VRE infection, and 50 had these catheters removed. The other patients had missing data regarding central venous catheter presence or removal at the time of VRE infection.
The underlying diagnoses of these patients for which the transplants were performed included 27 AML, 20 ALL, 10 myelodysplastic syndrome, 6 CML, 6 non-Hodgkin lymphoma, 3 CLL, 1 aplastic anemia, 1 myelofibrosis, 1 myeloproliferative disorder and 1 myeloid sarcoma.
Sixty-seven patients with VRE infection received myeloablative transplants including 32 with TBI-based conditioning, and 9 had RIC transplants of which all were TBI-based. Forty-two had unrelated donors and 18 had related donors with the graft sources consisting of BM for 46 and PBSC for 14 patients. Abbreviations: HCT-CI = hematopoietic cell transplantation-comorbidity index; MDS = myelodysplastic syndrome; NHL = non-Hodgkin lymphoma.
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The remaining 16 patients received umbilical cord blood (UCB) transplants. GVHD prophylaxis included 24 with tacrolimus plus MTX, 17 tacrolimus plus mycophenolate mofetil, 3 tacrolimus alone, 18 CSA plus mycophenolate mofetil, 13 CSA plus MTX and 1 CSA plus MTX plus extracorporeal photopheresis. Among those who developed VRE-B within 15 months after transplant, the median time to its initial occurrence was 46 days (range, 2-404 days) after transplant. Thirty-seven (49%) cases occurred during the initial transplant hospitalization with 36 occurring after myeloablative conditioning transplants and 1 after a RIC transplant. Among the other 39 patients who developed VRE infection after the initial transplant hospitalization, 31 occurred after transplants with myeloablative conditioning and 8 after outpatient RIC transplants. Thirty-five (46%), 52 (68%), 66 (87%) and 75 (99%) patients developed VRE infection within the first 30 days, 100 days, 6 months and 1 year after transplant, respectively.
Forty-eight (63%) patients with VRE-B also developed acute GVHD, but only 34 (45%) developed acute GVHD before VRE-B. The median time to VRE infection after developing acute GVHD was 76 days (range, 13-378 days). Forty (53%) had grade 2-4 acute GVHD with 27 (36%) before VRE infection at a median time of 61 days (range, 13-242 days) after acute GVHD diagnosis. Nineteen (25%) had grade 3-4 acute GVHD with 13 (17%) occurring before VRE infection at a median time of 45 days (range, 13-203 days) after acute GVHD diagnosis. Twenty-five Abbreviations: ANC = absolute neutrophil count; ATG = anti-thymocyte globulin; Flu = fludarabine; MMF = mycophenolate mofetil; TNC = total nucleated cell; UCB = umbilical cord blood; VRE = vancomycin-resistant enterococcus.
VRE bacteremia after alloHCT M Tavadze et al (33%) patients also developed chronic GVHD and 14 (18%) of these cases developed before VRE infection was diagnosed at a median time of 42 days (range, 1-259 days) after chronic GVHD diagnosis. For those patients who had GVHD before VRE infection, 34 cases of GVHD involved the skin, 30 the gastrointestinal tract and 9 the liver. Ten (12%) patients are alive at a median time from VRE-B to last follow up of 32 months (range, 3-128 months). Only 1(8%) of the The majority of patients, both alive and dead, received daptomycin as treatment for VRE-B (6 (60%) and 39 (53%), respectively). Among those who died, the next most common treatments included 14 (19%) linezolid, 9 (12%) quinupristindalfopristin and 7 (10%) gentamycin. None of the patients alive after VRE-B received quinupristin-dalfopristin, but one received linezolid and one gentamycin. Seven (8%) patients also had resistance to daptomycin and only one of them remained alive and had received tigecycline and amikacin.
Risk factors for developing VRE infection after alloHCT are presented in Table 3 . Transplantation occurring during the later years of the study period, higher HCT comorbidity score, not being in remission at the time of transplant, an underlying diagnosis of ALL, unrelated donor and an UCB donor were all significant risk factors on multivariable analysis for the development of VRE infection. To evaluate how the cumulative incidence of VRE infection had changed over time, we categorized our cohort into quartiles based on the date of transplantation. When VRE-B was analyzed as a time-varying covariate, there was no significant association with the development of T-cell complete donor chimerism, acute or chronic GVHD or underlying disease relapse. However, on multivariable analysis, VRE-B was significantly associated with worse OS (hazard ratio 4.45, 95% confidence interval 3.39-5.84, P o0.001) ( Table 4 ). Other significant prognostic factors for survival on multivariable analysis included year of transplant, male gender, age, number of prior chemotherapy regimens, higher HCT comorbidity score, not being in remission from the underlying hematologic disease at the time of transplant, unrelated donor and a recipient or donor positive pre-transplant CMV serostatus.
DISCUSSION
Vancomycin resistant enterococci have emerged as important pathogens in nosocomial infections for the past two decades. 17, 18 Our study identified five independent risk factors for the development of VRE infection after alloHCT including transplantation occurring during the later years of the study period, higher HCT comorbidity index, a diagnosis of ALL, having an unrelated donor, and UCB as a donor source.
The 10% incidence of VRE that we observed for this transplant population is comparable to that reported by the University of Minnesota. 19 They also found that delay in hematopoietic engraftment increased the incidence of VRE-B from 4.5% if engrafted before day 21 to 15% if engrafted between days 36 and 42. We observed that 42% of cases of VRE infection occurred within the first 30 days after transplant. Investigators at Memorial Sloan-Kettering Cancer Center have reported that VRE is emerging as the most common cause of bacteremia prior to engraftment. 20 These findings support our observation of an increased risk for VRE infection among recipients of UCB transplants, which is associated with delays in hematopoietic recovery.
Approximately half of our patients developed acute GVHD prior to being diagnosed with VRE infections. Although GVHD and the immunosuppressant therapy used for prophylaxis and treatment increase the risk of bacterial infection, 6, 7 we found no association of VRE infection with acute or chronic GVHD.
Acquiring an invasive VRE infection is a two-step sequence of events. Firstly, the patient gets colonized and secondly active infection develops. The risk factors for these two events are somewhat different. However, we did not screen our patients for VRE colonization and the purpose of our analysis was not to identify risk factors for colonization, but rather for VRE-B. A limitation of this analysis is insufficient data on the duration of neutropenia pre-transplant, the duration of central line placement, catheter complications, treatment of GVHD, prior infection, antimicrobial exposure, the occurrence of neutropenic enterocolitis as well as the accumulated length of stay in hospital the year before and after transplant. In addition, as the study period was over 14 years, differences in types of central venous catheters, preventative measures against infection, antimicrobial prophylaxis and therapy, prophylaxis and therapy of GVHD, and parenteral nutrition use may have had an effect on developing VRE infection.
Factors associated with mortality from VRE include hemodialysis, mechanical ventilation and malnutrition. 21 VRE infection has also been associated with increased mortality in patients with neutropenia, AML and those undergoing alloHCT. 10, 19, [22] [23] [24] [25] Mortality rates of 50-80% have been reported for such patients. 24, [26] [27] [28] The Mayo Clinic reported that most of their VREcolonized alloHCT patients developed VRE infection and such colonization was an independent risk factor for increased 100 day post-transplant mortality. 29 However, Kang et al. 30 only reported a 13% incidence of VRE-B among their alloHCT patients with prior VRE colonization and this was not an independent risk factor for developing VRE-B.
Furthermore, those who develop early onset VRE infection after alloHCT have a particularly dismal prognosis. We previously reported on 10 patients who developed VRE-B within 21 days of transplant and all died within 73 days of the VRE infection. 10 From the current report, VRE-B was identified as an independent risk factor for mortality in a multivariate analysis, but this is not evidence for a causative relationship. Other prognostic factors for mortality may also be related to a compromised immune status, but these may not be truly independent of each other. In addition, a limitation of this retrospective study is that the follow-up time for death after VRE-B is not uniform. VRE bacteremia after alloHCTVydra et al. 19 reported that the 30-day mortality after VRE infection for adults compared to pediatric alloHCT patients was 38 versus 20%. Although our current series included only adult patients and age was not found to be a prognostic factor for developing VRE infection, increasing age was an independent prognostic factor for worse survival. With the availability of RIC transplant approaches, more older patients have been able to undergo alloHCT, which likely contributes to the current incidence of VRE infection. Abbreviations: CI = confidence interval; HCT = hematopoietic cell transplantation; HCT-CI = hematopoietic cell transplant comorbidity index; HR = hazard ratio; RIC = reduced intensity conditioning; UCB = umbilical cord blood; VRE = vancomycin-resistant enterococcus. Multivariable model is based on data from 753 patients with 485 VRE events.
Daptomycin and linezolid have been reported to successfully clear 24% of VRE-B in hematology and alloHCT patients within 30 days. 31 However, the duration of VRE-B predicted mortality; 34% when bacteremia lasted more than 1 day, but 7% when bacteremia lasted 1 day. Although the majority of our patients received daptomycin, 88% died within a median of 1.2 months after VRE infection. Only four of these deaths were directly attributed to VRE, but this remained a significant independent risk factor for survival.
There is variation across centers regarding infection control measures used in alloHCT recipients. 32 We did not screen stools or perform rectal swabs to assess for VRE. Our patients were not placed in isolation for VRE infection.
The Centers for Disease Control and Prevention reported a 55% reduction in the incidence of central line-associated bacteremia from enterococcus in 2009 compared with 2001. 33 Future efforts to further lower this incidence may reduce the morbidity and mortality associated with VRE infection as well as costs and utilization of other health-care resources. We conclude that the incidence of VRE infection after alloHCT has increased over time and is highly associated with mortality although not usually attributable to VRE infection itself. Prompt diagnosis and treatment of such infections as well as investigation of novel therapies and preventive strategies for patients at high risk for VRE-B after alloHCT are warranted.
